Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)

NCT03710642 is registered in ClinicalTrials.gov with Alzheimer's Disease Cooperative Study (ADCS) as lead sponsor.

NCT NCT03710642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Phase
Phase 2
Overall status
Completed
Start date
October 23, 2018
Completion date
January 5, 2022
Enrollment
35 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, disruptive behavior